Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patient preference for subcutaneous versus intravenous nivolumab-based immunotherapy in melanoma
2023-504515-33-00Phase 2Authorised
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 6
01
Overview
Phase 2, open-label trial of nivolumab and relatlimab in melanoma (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Preference for subcutaneous administration. Planned start Feb 2024; status: authorised.
02
Drugs
nivolumabrelatlimab
03
Conditions
melanoma
Beyond the preview
Go deeper on 2023-504515-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504515-33-00.